On June 25, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported that three-year survival data from the Phase 1b C-800-01 study of botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2026, taking place July 1–4, 2026, in Munich, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation, delivered by Benjamin L. Schlechter, M.D., of Dana-Farber Cancer Institute, will provide updated findings from the fully enrolled cohort of 123 patients, including longer-term follow-up of durability of response and overall survival. The presentation follows the two-year overall survival data presented by Dr. Schlechter at ESMO (Free ESMO Whitepaper)-GI 2025 and reflects an additional year of follow-up from the Phase 1b study.

Presentation Details:

Abstract Title: Botensilimab + Balstilimab (BOT+BAL) in Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases: Extended Follow-Up and 3-Year Survival
Presenter: Benjamin L. Schlechter. M.D.; Dana-Farber Cancer Institute, Boston, MA, USA
Final publication number: 91P
Session Title: Poster Display Session
Location: Foyer
Date/Time: 2 July 2026 | 15:30 –16:30 CEST, 9:30-10:30AM EST

(Press release, Agenus, JUN 25, 2026, View Source [SID1234668953])